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ABSTRACT
Background
Leber congenital amaurosis (LCA) is a genetically heterogeneous group of retinal diseases
that cause congenital blindness in infants and children. Mutations in the GUCY2D gene that
encodes retinal guanylate cyclase–1 (retGC1) were the first to be linked to this disease group
(LCA type 1 [LCA1]) and account for 10%–20% of LCA cases. These mutations disrupt synthesis
of cGMP in photoreceptor cells, a key second messenger required for function of these cells.
The GUCY1*B chicken, which carries a null mutation in the retGC1 gene, is blind at hatching
and serves as an animal model for the study of LCA1 pathology and potential treatments in
humans.
Methods and Findings
A lentivirus-based gene transfer vector carrying the GUCY2D gene was developed and
injected into early-stage GUCY1*B embryos to determine if photoreceptor function and sight
could be restored to these animals. Like human LCA1, the avian disease shows early-onset
blindness, but there is a window of opportunity for intervention. In both diseases there is a
period of photoreceptor cell dysfunction that precedes retinal degeneration. Of seven treated
animals, six exhibited sight as evidenced by robust optokinetic and volitional visual behaviors.
Electroretinographic responses, absent in untreated animals, were partially restored in treated
animals. Morphological analyses indicated there was slowing of the retinal degeneration.
Conclusions
Blindness associated with loss of function of retGC1 in the GUCY1*B avian model of LCA1 can
be reversed using viral vector-mediated gene transfer. Furthermore, this reversal can be
achieved by restoring function to a relatively low percentage of retinal photoreceptors. These
results represent a first step toward development of gene therapies for one of the more
common forms of childhood blindness.
The Editors’ Summary of this article follows the references.
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Vertebrate vision begins with absorption of light by visual
pigments in retinal rod and cone photoreceptors. These
activated pigments trigger a G-protein-coupled cascade that
ultimately produces transient changes in the membrane
potentials of the photoreceptor cells by modulating intra-
cellular levels of cGMP, a key second messenger in this
cascade. Rapid light-induced decreases in levels of cGMP lead
to closure of cGMP-gated cation channels in the photo-
receptor plasma membrane, hyperpolarization of the cell,
and signaling to upstream neurons [1].
Precise regulation of cGMP synthesis and degradation,
processes mediated by retinal guanylate cyclase–1 (retGC1)
and cGMP phosphodiesterase (PDE), respectively, is critical to
the function and health of photoreceptors (for review see [2]).
Mutations in the PDE6B gene, which encodes the beta subunit
of cGMP PDE, lead to abnormal increases in cGMP levels in
photoreceptors, photoreceptor dysfunction, degeneration of
these cells, and blindness in mouse [3,4], dog [5,6], and human
[7]. Mutations in the AIPL1 gene destabilize cGMP PDE and
lead to photoreceptor dysfunction and a rapid retinal
degeneration in mouse [8,9] and human [10]. Mutations in
the gene encoding retGC1 that disrupt synthesis of cGMP
lead to a loss of photoreceptor function that presents as
blindness or severely compromised vision at birth followed by
photoreceptor degeneration in chicken [11,12] and human
[13–15].
The defective phototransduction second messenger system
in homozygous PDE6-deﬁcient mice was among the ﬁrst
targets for preclinical treatment using gene transfer [16–18].
The past decade has witnessed major progress in under-
standing disease processes in many animal models of human
retinopathy, and this has escalated efforts to develop
genetically based treatments (for review see [19]). To date,
the most dramatic preclinical successes in the application of
gene replacement strategies to treat inherited retinal disease
have targeted defects in the retinal pigment epithelium [20–
25] or in photoreceptor structure [26,27].
We have focused our efforts on developing a gene transfer
approach to correct the defective phototransduction second
messenger system of the GUCY1*B chicken. This animal
carries a deletion rearrangement in the gene encoding
retGC1 that produces a null allele [11]. The retinal disease
exhibited by these animals models the human early-onset
retinal degeneration known as Leber congenital amaurosis
(LCA) type 1 (LCA1). The LCA1 gene, GUCY2D on human
Chromosome 17p, was the ﬁrst to be identiﬁed in this disease
group and is estimated to account for 10%–20% of LCA
patients [13–15]. In both the GUCY1*B chicken [12,28] and in
patients with LCA1 [13], photoreceptor cell dysfunction
precedes degeneration of these cells. To test our hypothesis
that vector-mediated expression of retGC1 in the photo-
receptors of GUCY1*B chickens can restore photoreceptor
function and sight in these animals, we adopted an in ovo
treatment strategy that allowed us to treat the retina prior to
the appearance of pathology in these cells. In this report we
describe a series of experiments that represent a ﬁrst step
toward our goal of developing treatments for a subset of LCA
patients whose blindness is caused by GUCY2D mutations and
for whom there is currently no cure [29].
Methods
Vector Construction and Lentiviral Vector Packaging
A lentiviral vector system was chosen for use in these
experiments because the onset of expression of the transgene
is rapid and stable throughout the course of retinal develop-
ment [30,31], and these vectors are capable of carrying large
gene constructs [32]. The construction of the pTYF-EF1a-
PLAP vector has been described previously [33]. To construct
the pTYF-EF1a-GC1-IRES-eGFP vector, the cDNA encoding
bovine retGC1 was ampliﬁed in two parts from pSVL-ROS-
GC1 [34] using the following core primers with ClaI linkers
attached to the 59 ends: (1) 59-CCA TCG ATA GTT TAA ACG
AGC CCC GGA CTT and 59-GCC CAG CAC TGT TTC, and
(2) 59-GGC GAC GTC TTC AGT CT and 59-CCA TCG ATG
ACC CAG CCT CAC TTC C. The resulting fragments were
subcloned into the ClaI site of a pBSII SKþ shuttle vector
(Stratagene; http://www.stratagene.com) lacking the SacI site
and were joined using the unique SacI site located within the
ampliﬁed open reading frame to create pBS-bGC1. The
complete guanylate cyclase–1 (GC1) cDNA was removed from
pBS-bGC1 using ClaI and ligated into the ClaI site of the
pTYF-EF1a-IRES-eGFP linker vector (http://www.mbi.uﬂ.edu/
;rowland/vector.htm). The integrity of the GC1 coding
region was conﬁrmed by sequence analyses. Lentiviral vectors
were packaged using previously described methods [33].
In Vitro Analyses of Lentiviral Constructs and Virus
Transfection of DF1 cell cultures. Before packaging the
pTYF-EF1a-GC1-IRES-eGFP vector into lentivirus, we exam-
ined the function of the bicistronic transgene by monitoring
expression of retGC1 and green ﬂuorescent protein (GFP) in
transiently transfected immortalized chicken ﬁbroblasts (DF1
cells; ATCC; http://www.atcc.org). In vitro tests were per-
formed using DF1 cells because they allowed us to test the
functionalityofthepoliovirusIRESsequenceinthecontextof
chicken cell translational machinery. Cells were seeded on
tissue-culture-treatedglasscoverslips(FisherScientiﬁc;https://
www1.ﬁshersci.com) in 12-well plates and allowed to adhere
overnight. When the cells reached ;80% conﬂuence, 0.5 ml of
fresh medium was added to the cells, and 25 ll of the following
transfection mixture was added to the cells: 3 lg of pTYF-
EF1a-GC1-IRES-eGFP, 50 ll of plain Dulbecco’s modiﬁed
eagle medium, and 10 ll of Superfect reagent (Qiagen; http://
www.qiagen.com). Following a 4-h incubation period, fresh
medium was added to each well, and the cells were maintained
for 48 h before processing for immunocytochemistry.
Immunocytochemistry. Forty-eight hours after transfec-
tion, cells were ﬁxed using 4% paraformaldehyde for 5 min.
Cells were then incubated in blocking buffer (10% goat serum
in phosphate-buffered saline [PBS]) for 30 min. A rabbit
polyclonal antibody to GC1 (GC2; gift from A. Yamazaki) was
diluted 1/333 in PBS containing 1.0% bovine serum albumin
and 0.3% Triton X-100, and added to the cells, which were
then incubated overnight at 4 8C [35]. Primary antibody
detection was performed using goat anti-rabbit secondary
IgG tagged with the Alexa-594 ﬂuorophore (1/500 in PBS)
(Molecular Probes, Invitrogen; http://probes.invitrogen.com).
Immunostained cells were counterstained with 49,69-diamino-
2-phenylindole.
Transduction of TE671 cell cultures. After packaging the
pTYF-EF1a-GC1-IRES-eGFP vector into virus, the function of
the encoded GC1 enzyme was examined by transducing
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with the virus and then assaying these cells for GC1 activity.
TE671 cells were seeded into the wells of a 24-well plate and
grown overnight to ;90% conﬂuence. On the following day,
the cells in each well were infected with 0.3 ml of fresh
medium containing approximately 10
6 transducing units
(TUs) of either EF1a-GC1-IRES-eGFP or EF1a-eGFP virus.
After 24 h, the cells were trypsinized, seeded into T-25 ﬂasks,
and maintained by passaging two times a week. The cells were
harvested for use in GC1 activity assays after ;20 passages.
Cell pellets were snap-frozen in liquid nitrogen and stored at
 80 8C until use.
GC1 activity assays. Washed rod outer segment membranes
prepared from fresh bovine retinas [36] and cell membranes
of TE671 cells infected with either EF1a-GC1-IRES-eGFP or
EF1a-eGFP virus were reconstituted with recombinant
guanylate cyclase activating protein–1 (GCAP1) and assayed
for GC1 activity as previously described [37]. Calcium
concentration was calculated using the computer program
Chelator 1.00 [38] and adjusted to higher concentrations by
increasing the amount of CaCl2. All assays were repeated at
least twice.
Experimental Animals
A breeding colony of GUCY1*B Rhode Island Red (RIR)
chickens [39] is maintained at the University of Florida and is
cared for in accordance with National Institutes of Health
guidelines. Chickens were raised from hatching under 12-h-
on/12-h-off cyclic lighting. Three experimental groups were
included in this study: treated GUCY1*B chickens (n ¼ 7),
untreated GUCY1*B chickens (n ¼ 3), and wild-type, un-
treated RIR chickens (n ¼ 5).
Vector Injection and Hatching Procedures
Priortoinjection,onday0,eggswerewashedwithablendof
quaternary detergents (Biosentry RCL; http://www.antecint.co.
uk/main/biosentry-products27.htm) in a water bath preheated
to 43 8C. Dried eggs were then incubated without rotation on
their sides at 37.5 8C and 60% humidity. On embryonic day 2
(E2) (stage 10–12) [40], the position of the embryo was
determined using an egg-candling light and a 5- to 7-mm
opening was made in the eggshell overlying the embryo
without disturbing the membrane adjacent to the shell. Sterile
PBS (50–100 ll) was applied to the exposed membrane, which
was then removed. Viral vector was delivered to the neural
tube using a pulled glass capillary needle (tip diameter ;40
lm) held by a micromanipulator and connected to a manual
hydraulic microinjector (Sutter Instrument; http://www.sutter.
com). Approximately 0.5 ll of vector containing 0.03% fast
green dye was slowly injected into the ventricular space of the
developing neural tube with the aid of a dissecting microscope
(2.53). The opening in the eggshell was then sealed with
Paraﬁlm M (Fisher Scientiﬁc) using a warmed spatula to
adhere the ﬁlm to the shell. Post-injection, eggs were
incubated upright, large end up, at 37.5 8C and 60% humidity
and were slowly rocked three times per day (Sportsman
Incubator; GQF Manufacturing; http://www.gqfmfg.com). At
E18, eggs containing surviving embryos were moved to a
second incubator for hatching. From E18 through hatch, eggs
were incubated on their sides, were stationary, and were
maintainedat37.58Cand68%–70%humidity(AV-2Precision
Parrot Incubator, Avey Incubator; http://www.aveyinc.com).
Post-hatchchickswererearedfor3to5dinanOctagonTLC-4
brooder (Brinsea; http://www.brinsea.com) and then trans-
ferred to the University of Florida animal housing unit.
Behavioral Analyses
Animals were tested for the presence of both reﬂexive and
volitional visual behaviors every 3 to 10 d for 6 wk. Reﬂexive
visual responses were assessed using an optokinetic nystag-
mus (OKN) paradigm. The OKN reﬂex is driven primarily by
visual stimuli processed by the peripheral regions of the
retina. The reﬂex is manifest as a compensatory head
movement of the animal in an attempt to ﬁxate a moving
stimulus. The stimuli were two high-contrast vertical square
wave gratings with spatial frequencies of 0.065 or 0.26
cycles degree
 1 (bar widths of either 5 cm or 1.25 cm,
respectively). Stimuli were presented in the form of a rotating
drum (average speed 14.6 rpm) and were evenly illuminated
from above (60-W incandescent bulb). The animals were held
stationary in the center of the drum while it was rotated in
both clockwise and counterclockwise directions. The behav-
ior of the animals was also examined when the stimulus was
not moving, serving as a reference point for evaluation of the
behaviors elicited by the moving stimuli. A positive OKN
response was characterized by a smooth head movement in
the direction and at the speed of stimulus rotation followed
by a rapid head movement in the opposite direction.
Behavior was recorded (Nikon Coolpix Digital Camera and
Video Recorder; http://www.nikon.com) and analyzed for the
presence of OKN responses using a zero to three scoring
system: zero, no OKN response; one, inconsistent or unidirec-
tional responses to the lower spatial frequency grating; two,
consistent bidirectional responses to the lower spatial
frequency grating; three, consistent bidirectional responses
to the higher spatial frequency grating.
Volitional visual responses were assessed by placing
animals in a testing environment that contained novel visual
stimuli including colored candies, aluminum foil, and metal
objects. Volitional visual behavior is driven primarily by
stimuli processed by the central/foveal regions of the retina.
The animal’s interest in its visual environment drives this
behavior. Animals were exposed to the testing environment
for periods of approximately 3 to 5 min, and behavior was
video-recorded and analyzed using a zero to three scoring
system: zero, no visual behavior, with random head drift; one,
evidence of orientation to surroundings, with no random
head drift detected; two, head movements coordinated with
the presence and/or movement of visual stimuli; three,
pecking of visual targets and stimuli.
Electroretinograms
The pupils of dark-adapted (.12 h) animals were dilated
(repeated topical administration of vecuronium bromide,
proparacaine HCl, benzalkonium chloride, and tropicamide)
over a 30-min period prior to the recordings. The animals
were then anesthetized using a mixture of ketamine HCl (10
mg/kg) and xylazine (2.5 mg/kg) delivered intramuscularly. A
quarter of the initial dose was given as needed during the
recording session to maintain anesthesia. Anesthetized
animals were placed in a supine position with their heads
resting on a head holder. Full-ﬁeld electroretinograms (ERGs)
were recorded from the right eye of each animal using
custom-made contact lens electrodes (Hansen Ophthalmics,
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and the electrode was held in place by a stereotaxic
apparatus. A platinum needle placed in the skin above the
eye served as reference. ERGs were recorded using a
commercially available ganzfeld- and computer-based system
(ColorDome and Espion Console, Diagnosys; http://www.
diagnosysllc.com). Recordings began with dark-adapted ERG
luminance-response functions elicited with increasing inten-
sities of white ﬂashes ( 3.2 to þ0.8 log cd s m
 2; 0.5 log unit
steps; 2-s interstimulus interval; digital ﬁlter disabled). For
low-intensity stimuli, 4–10 responses were recorded and
averaged. For the highest-intensity stimuli, 2–6 responses
(.15-s interstimulus interval) were recorded. Upon comple-
tion of the dark-adapted stimulus series, the animals were
light-adapted to a 30-cd m
 2 white background, and the ERGs
elicited by 29-Hz ﬂicker stimulation (white;þ0.8 log cd.s m
 2)
were recorded and averaged (20 responses). In some cases,
250–750 responses were recorded to detect submicrovolt-
amplitude ﬂicker ERGs. The amplitudes of the ERG wave-
forms were measured conventionally: a-waves were measured
from baseline to the trough, b-waves were measured from
baseline or from the a-wave trough to the positive peak, and
29-Hz ﬂicker amplitudes were measured from trough to peak.
Tissue Collection for Histological and Molecular Analyses
The animals were sacriﬁced within 1 wk of the last
behavioral testing period. Animals were anesthetized with
an intramuscular injection of ketamine (16 mg/kg) and
euthanized using a protocol approved by the University of
Florida Institutional Animal Care and Use Committee. The
eyes were then rapidly enucleated and the anterior segment
and vitreous body of each eye were dissected away. The
posterior eye cup of the right eye was placed in 4%
paraformaldehyde and ﬁxed overnight at 4 8C. Following
ﬁxation, one half of the bisected right eye cup was processed
for semi-thin plastic histology, and the other half was
processed for frozen sectioning and extraction of genomic
DNA. The left eye cup was bisected along the superior/
inferior midline axis, and equal portions of the retina/retinal
pigment epithelium/choroids were removed, placed in sealed
tubes, rapidly frozen in liquid nitrogen, and stored at  70 8C
until use for RNA analyses.
To permit use of the right and left retinas of treated
animals in our analyses, we determined if delivery of the virus
via the neural tube produced similar transduction percen-
tages in both eyes. Three embryos were injected with 0.5 llo f
pTYF-EF1a-PLAP lentivirus (5 3 10
9 TUs/ml) to compare the
pattern and percent transduction of left and right retinas. On
E10, the embryos were sacriﬁced and the retinas were
processed for PLAP staining and analyzed as described
previously [30,33]. The patterns and percent transduction
values for the left and right retinas of individual animals were
similar (41%, 39%; 18%, 13%; 9%, 15%). The variability
observed in the percent transduction between animals was
dependent on the quality of the embryonic injection and
decreased as percent transduction increased. No striking
interocular asymmetry was observed in the percent viral
transduction within individual animals.
Retinal Immunohistochemistry and Light Microscopy
Following ﬁxation in 4% paraformaldehyde, the right eye
of each animal was bisected along the superior/inferior
midline axis: the temporal portion of each eye cup was
processed for immunohistochemical analyses while the nasal
portion was processed for semi-thin plastic analyses. Tissues
designated for immunohistochemical analyses were cryopro-
tected by soaking overnight in a 30% sucrose (wt/vol)–PBS
solution, sectioned (14 lm), and stored at 30 8C until stained.
Prior to immunostaining, the tissues were dried overnight,
rinsed in PBS, and permeabilized and blocked for 1 h in PBS
containing 0.3% Triton X-100, 1% bovine serum albumin,
and 10% goat serum. GFP was detected using a polyclonal
antibody (generously provided by W. Clay Smith, University
of Florida, Gainesville, Florida, United States) diluted 1:500 in
primary dilution buffer (PBS containing 1% bovine serum
albumin and 10% goat serum). Sections were incubated with
the primary antibody overnight at 4 8C. The primary antibody
was visualized by labeling with a goat anti-rabbit IgG
secondary antibody tagged with the Alexa-488 ﬂuorophore
(Molecular Probes, Invitrogen) diluted 1:500 in primary
dilution buffer. Sections were counterstained with 49,69-
diamino-2-phenylindole, mounted in Gel/Mount aqueous
media (Biomeda; http://biomeda.com), coverslipped, and
sealed with Permount resin. Tissues designated for semi-thin
plastic analyses were dehydrated through a graded series of
ethanol solutions (50%, 70%, and 80%) and embedded in JB-
4 Plus (Electron Microscopy Sciences; http://www.emsdiasum.
com/microscopy) using the manufacturer’s protocol. Plastic
embedded tissues were sectioned (1.5 lm), stained with 1%
toluidine blue in 1% (wt/vol) sodium borate, and coverslipped
using Permount resin. Immunohistochemical and plastic
sections were examined and photographed using a Zeiss
Axioskop 2 plus (http://www.zeiss.com) ﬁtted with a Spot
image acquisition system (Diagnostic Instruments; http://www.
diaginc.com).
The immunostained and semi-thin plastic sections were
analyzed to obtain information regarding the extent of viral
transduction and the effects of the treatment on retinal
morphology, respectively. We were unable to estimate the
percent viral transduction of the retina by examining ﬂat-
mounted retinas because GFP expression was too low to allow
direct visualization of the transduced cells. Low protein
expression is frequently observed from the second cistron of
IRES-based bicistronic expression cassettes in vivo [41].
Information about the distribution of transduced cells was
obtained by analyses of GFP immunoﬂuorescence of serial
sections cut along the superior/inferior axis of the right eyes
of the treated animals. Immunostained serial retinal sections
were each divided into four regions relative to the optic nerve
and were designated far superior (FAR SUP), superior (SUP),
superior optic nerve (SUP ON), and inferior optic nerve (INF
ON). Each region was assigned a percent transduction score
by an independent observer that was based on the number of
GFP-positive cells within the region. These scores were
plotted to yield 3-D graphic representations of transduction
across the 500-lm retinal expanse using SigmaPlot v8.0
(Systat; http://www.systat.com). To assess the effects of treat-
ment on retinal morphology, the total width of the retina
extending from the outer limiting membrane to the ganglion
cell layer was measured at 100-lm intervals within each of the
four retinal regions. Measurements were made from digital
images of representative semi-thin retinal sections using
Adobe Photoshop v7.0 (Adobe; http://www.adobe.com). For
each region, the retinal widths of the treated retinas were
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the corresponding regions in age-matched GUCY1*B un-
treated retinas.
Genomic and Reverse Transcription PCR
Genomic DNA was extracted from 25 mg of retina/pigment
epithelial tissue taken from the right eye that had been ﬁxed
and cryoprotected but not sectioned. The tissues were soaked
in PBS to remove the sucrose, and DNA was extracted from
the tissue using a DNAeasy kit (Qiagen). Total RNA was
extracted from retina/pigment epithelium tissue that had
been removed from the left eye and stored at  70 8C. The
frozen tissue was pulverized under liquid nitrogen, and RNA
was extracted using an RNeasy kit (Qiagen) according to the
manufacturer’s recommended protocol that included treat-
ment of the RNA samples with RNA-free DNAse to remove
trace quantities of genomic DNA. Known copy numbers of
pTYF-EF1a-GC1-IRES-eGFP plasmid DNA ranging from
3,000 to 300,000 copies were prepared and ampliﬁed in
parallel with the genomic DNA samples.
The plasmid DNA standards, genomic DNA, and total RNA
were ampliﬁed using primers that spanned the IRES-eGFP
elements present in the lentiviral transgene (sense: 59-TTT
CCC CGG TGA TGT CGT; antisense: 59-GCC GGT GGT GCA
GAT GAA). The reverse transcription (RT)–PCR analyses
included ampliﬁcation of chicken b-actin mRNA (sense: 59-
TGC TGC GCT CGT TGT TG; antisense: 59-GTC ACG GCC
AGC CAG AT) to control for the quality and quantity of RNA
in each sample and the efﬁciency of the RT reaction. PCR
ampliﬁcation of standard and genomic (0.5 lg of DNA
template) DNA was carried out in 50-ll reactions. RT-PCR
reactions were carried out in two steps. Total RNA (1 lg) was
reverse transcribed in a 50-ll reaction volume. Aliquots of
the RT reaction were then ampliﬁed for GC1 (15 ll) and b-
actin (3 ll) transcripts in separate reactions (50-ll ﬁnal
volume). Components for the genomic and RT-PCR reactions
were obtained from an AmpliTaq Gold RT-PCR kit (Applied
Biosystems, http://www.appliedbiosystems.com). The reaction
parameters used to amplify the GC1 transgene and its
transcript were 95 8C for 2 min; 35 cycles of 95 8C for 1
min, 61 8C for 1 min, and 72 8C for 1 min; 72 8C for 10 min;
and 4 8C soak. The reaction parameters used to amplify the b-
actin transcript were the same as above except that
ampliﬁcation was carried out for 30 cycles. Aliquots (20 ll)
of the PCR reactions were separated on a 1% agarose gel
containing 32 nM ethidium bromide, and photographed and
analyzed using a Gel Doc 1000 system and Quantity One
software (Bio-Rad; http://www.bio-rad.com). The RT-PCR
analyses were repeated three times. For each RT-PCR trial,
the quantity of transgene mRNA in each sample was
normalized to the average amount of b-actin mRNA present
in the samples.
The number of integrated vector transgenes in the genomic
DNA extracted from the treated tissues was estimated by
comparing the amount of product obtained in these reactions
to that obtained from PCR ampliﬁcation of known copy
numbers of the respective plasmid DNA. The genomic DNA
and standard reactions were ampliﬁed and analyzed under
identical conditions and were repeated three times. When
imaging the PCR gels, care was taken to ensure that the signals
were below saturation. The intensity values for the standards
obtained from three independent trials were plotted and
analyzed using SigmaPlot 8.0 (Systat). The number of vector
transgene copies present in the genomic DNA samples was
calculated using the equation for the best-ﬁt sigmoid curve.
These values were converted to vector transgene copies per
genome copy (transgenes/genome) using the value of 380,000
genome copies/0.5 lg of chicken DNA [42].
Statistical Analyses
The morphological data obtained from the semi-thin
plastic sections were analyzed using a one-sample t-test to
determine if the mean percent change in retinal thickness of
treated animals relative to untreated GUCY1*B age-matched
controls was signiﬁcant in the four retinal regions examined.
Results
In Vitro Characterization of the pTYF-EF1a-GC1-IRES-eGFP
Vector
Prior to packaging the pTYF-EF1a-GC1-IRES-eGFP vector,
the function of the transgene was examined by transfecting
DF1 cells with the plasmid and immunostaining the cells for
GC1. DF1 cells transfected with pTYF-EF1a-GC1-IRES-eGFP
(Figure 1A) stained positively for bovine GC1 and in many
cases exhibited GFP ﬂuorescence indicating that both
cistrons of the bicistronic transgene were being expressed
(Figure 1B). Not all GC1-positive cells were GFP-positive. The
low levels of GFP protein in these cells is consistent with
several reports of reduced protein expression from cistrons
located downstream of IRES elements [41]. The pTYF-EF1a-
GC1-IRES-eGFP vector was packaged into virus, and the
function of the transgene following integration was examined
using TE671 cells. TE671 cells infected with EF1a-GC1-IRES-
eGFP lentivirus expressed GFP (data not shown). Biochemical
analyses of membrane fractions prepared from these cells
revealed that the GC1 protein encoded by the transgene
exhibited robust GCAP1-dependent activity that was modu-
lated by calcium in a physiological manner (Figure 1C) [43].
Since we used cDNA encoding bovine GC1 in our vector
constructs, we also conducted experiments to examine the
ability of chicken GCAP1 to activate bovine GC1 under
physiological conditions. The results of these analyses showed
that activation of bovine GC1 by chicken GCAP1 is calcium-
dependent and that the level of activation is comparable to
that induced by bovine GCAP1 (Figure 1D).
In Vivo Lentiviral Treatment Restores Optokinetic and
Volitional Visual Behaviors
Seven GUCY1*B embryos were treated with EF1a-bGC1-
IRES-eGFP lentivirus. Of the seven treated animals, six
exhibited varying degrees of sighted behavior over the course
of the 4- to 5-wk testing period. One treated animal failed to
exhibit sight as measured by behavioral testing. We con-
ducted electrophysiological tests on this animal, but did not
process its retinas for molecular or morphological analyses.
The visual capabilities of the six treated animals exhibiting
sight were assessed by examining their optokinetic reﬂexes
(Figure 2A; Video S1) and volitional visual behaviors (Figure
2B; Video S2). These tests allow assessment of visual function
subserved by different regions of the retina and central
nervous system. The OKN test is dominated by the function
of the peripheral retina while the volitional test is dominated
by the function of the central/foveal retina [44–46]. All
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Recovery of Vision in Model of LCA1treated, sighted animals exhibited robust OKN responses to
the two different spatial frequencies tested (Video S3), with
an overall group mean score of 2.23. Volitional, sight-directed
pecking behavior was observed in treated animals as early as 3
d post-hatching. They also exhibited high levels of explor-
atory behavior and were able to peck at a variety of objects
within their visual ﬁelds (Video S4). The mean volitional
behavior score for the six treated animals over the entire
study period was 2.05. On the ﬁnal day of testing, ﬁve of the
six treated animals received OKN scores of three and
volitional behavior scores of either two or three. The visual
behavior scores of the remaining animal dropped during the
last week of the study. At the time of sacriﬁce, this animal did
not show any evidence of volitional sight. Wild-type and
untreated GUCY1*B animals received mean scores of 3.0 and
zero, respectively, on both the OKN and volitional behavior
tests. A summary of the vision test results for the six treated
animals exhibiting sight is shown in Figure 2C and 2D.
Retinal Electrophysiology Also Indicates Treatment
Restores Function
Electroretinography conducted under both dark- and light-
adapted conditions was used to assess photoreceptor-medi-
ated retinal function in wild-type, untreated GUCY1*B, and
treated GUCY1*B chickens 3–4 d prior to sacriﬁce. All
animals were 31–37 d of age at the time of testing. ERGs in
wild-type and untreated GUCY1*B chickens differed dra-
matically (Figure 3A). Dark-adapted wild-type animals had
ERG responses with a-wave (photoreceptor origin) and b-
wave (bipolar cell origin) components that increased in
amplitude with increasing stimulus intensity (Figure 3A, left).
Dark-adapted, untreated GUCY1*B animals failed to produce
measurable ERG responses to stimuli of even the highest
intensities (Figure 3A, middle). Light-adapted wild-type
chickens had large-amplitude cone-mediated ERG responses
when presented with a 29-Hz ﬂicker stimulus in the presence
of rod-desensitizing background illumination (Figure 3B,
left). Light-adapted, untreated GUCY1*B animals had no
detectable ﬂicker ERG responses (Figure 3B, middle). Treat-
ment of GUCY1*B animals with EF1-bGC1-IRES-eGFP
lentivirus restored retinal function (Figure 3A and 3B, right).
Five of seven (71%) treated animals had ERG responses to
single ﬂashes under dark-adapted conditions and to ﬂickering
stimuli under light-adapted conditions. The shapes of these
responses were similar to those generated by wild-type
Figure 1. In Vitro Analyses of the Function of the pTYF-EF1a-GC1-IRES-eGFP Vector and Virus
(A) Diagram of the bicistronic vector indicating production of bovine GC1 and GFP proteins from a single transcript.
(B) DF1 cells transiently transfected with the vector and subsequently analyzed for expression of bovine GC1 and GFP. Cells immunostained with
antibody recognizing bovine GC1 also expressed GFP.
(C) Comparison of GC1 activity measured in bovine rod outer segments (ROS), TE671 cells transduced with EF1a-GC1-IRES-eGFP virus, and TE671 cells
transduced with the control virus, EF1a-eGFP. Activity was assayed in the presence or absence of bovine GCAP1 under both high- and low-calcium
conditions and is expressed as nanomoles of cGMP produced per minute.
(D) Examination of ability of chicken GCAP1 to activate bovine GC1 under physiological conditions. GC1 activity was measured in preparations of bovine
rod outer segments in the presence and absence of bovine GCAP1 and chicken GCAP1 under high- and low-calcium conditions. All assays were
conducted in triplicate. Bars represent mean 6 SEM.
DOI: 10.1371/journal.pmed.0030201.g001
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animals had no detectable responses (Figure 3C). The
amplitudes of the ERG a-waves in the ﬁve responding animals
(6.6 6 1.3 lV [mean 6 standard deviation]) were 6% of the
wild-type response (105.8 6 36.0 lV), suggesting that photo-
transduction had been restored in a subset of photoreceptors.
The two treated animals that did not exhibit visual behavior
failed to produce ERGs that were distinguishable from noise
(Figure 3D).
The Number of Integrated Transgenes per Genome Is
Related to Treatment Efficacy
Quantitative genomic PCR was carried out on DNA
extracted from the right eyes of the six treated animals that
exhibited visual behavior to obtain a measure of the
efﬁciency of the viral treatment. The retinas of the seventh
animal, which did not exhibit evidence of sighted behavior
following treatment, were not processed for molecular or
morphological analyses. The DNA samples were analyzed on
three different days, and each reaction set included ampli-
ﬁcation of DNA standards containing known copy numbers
of the transducing vector. The primers were designed to
amplify a 638-bp product that spanned the IRES-eGFP
elements within the transgene (Figure 4A). The lentiviral
transgene was detected in all six samples obtained from the
treated animals; no product was ampliﬁed from untreated
GUCY1*B, wild-type RIR, or water control reactions (Figure
4B). The amount of PCR product obtained in all experimen-
tal samples fell within the linear portion of the standard
ampliﬁcation curve (Figure 4C) used to calculate the number
of copies of the viral transgene within each sample. The
estimated number of integrated viral transgenes per genome
in the retinas of the six treated animals ranged from 0.12 to
0.02 with a mean value of 0.07 6 0.01(mean 6 standard error
of the mean [SEM]). A comparison of the integrated viral-
transgene-per-genome values and the ERG and behavioral
data obtained from the experimental and control animals at
the end of the 6-wk study is shown in Figure 4D. A noteworthy
ﬁnding is that the animal with the lowest transgene copy
number was the animal that toward the end of the study
scored poorly on the visual behavior tests and had no
measurable ERG responses.
RT-PCR Analyses and GFP Immunostaining Confirm
Transgene Expression
RT-PCR analyses were carried out to examine transgene
expression in the retinas of treated animals. Ampliﬁcation of
aliquots of reverse-transcribed RNA revealed that the tran-
script derived from the viral transgene was present in all six
of the treated retinal samples. The 638-bp PCR product for
the transgene was not detected when the RT step was omitted
from the procedure, nor was it detected in GUCY1*B
untreated or wild-type retina samples. All samples contained
approximately equal amounts of b-actin mRNA as deter-
mined by the staining intensity of the 538-bp b-actin product.
The amount of transgene and b-actin transcript in each
sample was quantiﬁed, and the amount of transgene mRNA
was normalized to the average amount of b-actin mRNA
detected across all samples run in that particular assay. The
relative amount of transgene mRNA present in each of the
experimental samples, determined from three independent
assays, ranged from a high of 144 to a low of 19, with a mean
value of 94 6 12 (mean 6 SEM). In general, transgene mRNA
levels correlated with estimates of the number of integrated
transgenes per genome within animals. Variations in these
measures were likely due to sampling variability arising from
Figure 2. Optokinetic and Volitional Behavior Tests Indicate Treatment
Efficacy
(A) Optokinetic reflex (OKN) exhibited by 21-d-old, wild-type RIR chicken.
Two frames of Video S1 (4.3 s between frames) are shown illustrating the
head movement observed in birds in response to counterclockwise
rotation of the 0.26-cycles degree
 1 (bar width ¼ 1.25 cm) stimulus.
(B) Volitional visual behavior exhibited by treated GUCY1*B animal 2 on
day 7. Two frames of Video S4 are shown illustrating the animal’s abilities
to perceive and peck at objects within its visual field.
(C and D) Graphic summaries of the behavioral test results for the six
treated animals that exhibited sighted behavior. (C) Graphs showing the
optokinetic scores (0–3) for the six treated animals as a function of age.
(D) Graphs showing the volitional behavior scores (0–3) for the six
treated animals as a function of age. The graphs are color coded by
animal.
DOI: 10.1371/journal.pmed.0030201.g002
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different tissue samples for these analyses.
The distribution of transduced cells within treated retinas
was determined by examining serial sections of the right eye
cup taken along the vertical meridian (Figure 5). Each section
was divided into four contiguous regions, and the percent of
retinal cells positive for GFP was estimated for each region
(Figure 5A). In all retinas examined, greater than 90% of the
GFP staining was localized to the photoreceptor cell layers
(Figure 5C). The estimates of percent GFP staining observed
in each 14-lm section were used to create a topographical
map of the percent GFP staining observed within the 500-lm
region for each animal. The results obtained for two of the six
treated animals (animals 1 and 2; Figure 5D) illustrate the
variation observed in the distribution of transduced cells in
the 500-lm region selected for these analyses. The estimates
for the number of integrated transgenes per genome for
animals 1 and 2 were 0.08 and 0.07, respectively. The spatial
distribution of transduced cells observed in the retinas of
these animals was similar to that observed in our analyses of
ﬂat-mounted EF1a-PLAP-treated retinas (Figure 5B). Based
on the percent transduction estimates obtained for retinas
treated with the EF1a-PLAP virus, a conservative estimate for
the percent transduction of the retinas treated with the EF1a-
GC1-IRES-eGFP virus would be 15%–40% of the photo-
receptor population, with the actual value depending on the
quality of the embryonic injection.
Morphometric Analyses Suggest That Lentiviral Treatment
Slows Retinal Degeneration
The histopathology associated with the absence of GC1 in
the GUCY1*B retina has been well-documented [12,47].
Degeneration ﬁrst appears 7–10 d post-hatch and is limited
to the photoreceptor cells. By 21 d of age, the number of
identiﬁable outer segments is signiﬁcantly reduced, and at
115 d of age, very few photoreceptors remain in the central
retina and gross pathological changes are present in the
Figure 3. Retinal Electrophysiology Rescued in Treated Eyes
(A) Comparison of dark-adapted ERGs in response to increasing intensities of light in a GUCY1*B/GUCY1*B animal injected with EF1a-bGC1-IRES-eGFP
(‘‘treated’’) compared to a control animal (‘‘untreated’’). ERGs in the untreated animal are nondetectable, in contrast to the sizeable ERGs evoked in the
treated animal. Results from a wild-type animal are shown in the left column for comparison.
(B) Light-adapted 29-Hz flicker ERGs in the same animals as shown in (A) demonstrate restoration of responses after treatment.
(C) Overlapping waveforms are ERGs elicited by 0.8 log cd s m
 2 white flashes presented in dark-adapted (‘‘DA 1 Hz’’) and light-adapted (‘‘LA Flicker’’)
states in all treated animals compared to wild-type controls. Functional rescue was observed in five (top waveforms) of the seven treated animals,
whereas two (bottom waveforms) showed responses indistinguishable from noise.
(D) Summary parameters of dark-adapted photoreceptor (a-wave) and post-photoreceptor (b-wave) function, as well as light-adapted flicker amplitude
in treated animals as compared to untreated and wild-type animals. Five of seven treated animals showed amplitudes substantially larger than
untreated animals but smaller than wild-type controls (gray symbols; mean 6 standard deviation).
DOI: 10.1371/journal.pmed.0030201.g003
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have progressed to peripheral regions of the retina and little
remains of the photoreceptor cell layer. Sections of retinas of
the right eyes of treated animals were compared to those of
age-matched wild-type and GUCY1*B untreated animals to
determine if the viral treatment altered the histopathology.
The results suggested that treatment may have slowed retinal
degeneration in some animals but did not prevent degener-
ation (Figure 6A). The best preservation of the retina was
observed in animal 1, as evidenced by increased numbers of
nuclei within the outer nuclear layer and increased thickness
of the inner plexiform layer relative to untreated GUCY1*B
retina. In contrast, animal 6 had severe loss of cells from the
outer nuclear layer across all regions examined, and the
retinal pigment epithelium had changes characteristic of the
late-stage degeneration usually observed in untreated animals
[12]. The retinal changes were quantiﬁed by measuring the
distances between the outer limiting membrane and the
ganglion cell layer within each of the four regions sampled.
These measures were expressed as percent change in retinal
thickness relative to that observed in untreated GUCY1*B
retinas (Figure 6B). The results of these analyses revealed that
the thickness of all of the treated retinas relative to untreated
retinas was signiﬁcantly greater in the SUP ON (t[5]¼2.9, p ,
0.05) and INF ON (t[5]¼3.5, p , 0.05), the two regions of the
retina that normally undergo the most rapid degeneration in
untreated GUCY1*B retinas [12]. The SUP region of the
retinas of four of the six treated animals also showed signs of
slowed degeneration, but these changes were not found to be
signiﬁcant. Analyses of the FAR SUP region revealed that one
treated animal showed signs of unusually severe retinal
degeneration in this region; this region in the remaining ﬁve
treated animals was not signiﬁcantly different from that of
untreated retinas (data not shown).
Figure 4. Quantitative Genomic PCR Estimate of Integrated Viral Trangenes per Genome
(A) Diagram of integrated viral transgene and location of PCR primers spanning the IRES-eGFP junction that were used to amplify the transgene.
(B) Ethidium-bromide-stained gel showing 638-bp product (indicated by arrow) amplified from the experimental and standard reactions. Lanes 1–6
contain samples amplified from the six treated animals exhibiting restored sight. No product was observed in untreated GUCY1*B (lanes 7 and 8) or
wild-type (lane 9) chickens. A blank water control is shown in lane 10. Lanes 11–14 contain product amplified from 300,000, 150,000, 30,000, and 15,000
copies of the transducing vector. DNA size ladders, 1 kb and 123 bp, were run to the left of the samples and standards.
(C) Plot of amount of product obtained from the standard PCR reactions (black) best fit with a sigmoid curve (f¼y0þa/(1þexp( (x x0)/b))
c with r
2¼
0.999 . The products obtained from each experimental sample (red) fell within the linear portion of the amplification curve, and the number of
transgenes present in each sample was calculated using the equation for the best-fit curve. Individual values plotted are mean 6 SEM (n ¼ 3).
(D) Comparisons of integrated viral transgenes per genome, dark-adapted ERG b-wave amplitudes (1 Hz), volitional behavior scores, and optokinetic
reflex scores. The data for the ERG and behavioral tests were collected at the end of the 6-wk study period. The results for the six treated animals
exhibiting sight and for age-matched untreated GUCY1*B and wild-type RIR animals are shown. NA, not assayed; ND, not detected.
DOI: 10.1371/journal.pmed.0030201.g004
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Expression of GC1 in GUCY1*B Photoreceptors Restores
Cell Function and Vision
This study is the ﬁrst to our knowledge to demonstrate
restoration of sight in an animal model of LCA1. Using a
lentiviral vector system and an in ovo approach, we success-
fully delivered normal copies of GC1 transgenes to retinal
cells of GUCY1*B chickens, the expression of which was
sufﬁcient to restore function to photoreceptor cells as
measured by ERG. Importantly, the transduced photorecep-
tors supported robust visual behavior in treated animals. In
the six treated animals exhibiting sighted behavior, the ERG,
Figure 5. Immunohistochemical Analyses of GFP Expression in Treated Retinas
(A) Schematic of the right eye cup that shows how the retina was apportioned for analyses. The right eye of each animal was bisected along the vertical
meridian. One half was processed for immunohistochemical (IHC) analyses and the other for detailed histological analyses. The retinal sections were
divided into four regions (FAR SUP, SUP, SUP ON, and INF ON) to simplify analyses.
(B) Flat-mount retinas stained to reveal pattern of transduction obtained following neural tube delivery of 0.5 ll of EF1a-PLAP virus (10
9 TUs/ml). The
percent transduction for the left (left panel) and right (right panel) eyes of two of the three animals analyzed is shown.
(C) FAR SUP region of a treated retina immunostained for GFP. Arrows indicate staining in photoreceptor cell bodies. GFP staining is also visible in the
inner segments and outer segments of these cells. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segments; ONL,
outer nuclear layer; OS, outer segments.
(D) Topographical distribution of GFP-expressing cells in treated right eyes from treated animals 2 (left) and 1 (right). The percent transduction of each
of the four retinal regions was plotted on the z-axis as a function of location along the superior–inferior axis of the eye (x-axis) and distance from the
midline (y-axis). These analyses represent the results obtained from serial sections over 500 lm beginning at the midline axis and moving laterally.
DOI: 10.1371/journal.pmed.0030201.g005
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genome data were indicative of overall treatment efﬁcacy.
Larger ERG responses, better preserved retinal morphology,
and higher integrated transgene numbers were observed in
animals that received the highest visual performance scores,
while the absence of ERG responses, poor retinal morphol-
ogy, and low integrated transgene numbers were associated
with animals exhibiting poor visual performance.
Achieving Long-Term Vision Restoration in LCA1
Gene-based therapies of autosomal recessive retinal degen-
erative diseases are based on the seemingly simple principle
that expression of a viable copy of a defective gene will
produce functional protein, restore function to disabled cells
and tissues, and prevent degeneration. Our therapy success-
fully addresses the ﬁrst two goals but falls short of preventing
retinal degeneration. Slowed but progressive retinal degen-
eration has also been observed in other successful gene
transfer experiments for photoreceptor disease (for examples
see [16,18,48]). To produce an effective, long-term therapy,
degeneration must be prevented or limited.
The patchy transduction pattern generated by our treat-
ment (Figure 5B) leads to an intermingling of nontreated,
dysfunctional photoreceptor cells with treated, functioning
cells. Thus, the phenomenon known as the ‘‘bystander’’ effect,
or nonautonomous cell degeneration, may be at play [49,50].
In many inherited photoreceptor diseases linked to genes
whose expression is limited to rod cells, cone photoreceptor
cells also degenerate. The retinal degeneration patterns
observed in aggregation embryos created from normal and
mutant mice expressing mutant rhodopsin (Pro347Ser) [51]
and in hemizygous transgenic female rds
 /  mice carrying a
transgene encoding normal rds/peripherin on the X-chro-
mosome [52] further illustrate this phenomenon. Degener-
ation of photoreceptors expressing abnormal proteins had a
negative impact on the ability of otherwise healthy cells to
survive, a trend that was tempered in retinas containing
higher percentages of normal cells. If the ratio of nontreated
to treated cells is high in our animals, then degeneration of
the nontreated cells could be adversely affecting survival of
the treated cells. The simplest approach to achieve long-term
restoration of sight in our paradigm may be to increase the
total number and/or density of photoreceptor cells trans-
duced by the viral vector. By increasing the titer of the
injected virus from 10
9 to 10
10 TUs/ml, for example, we can
effectively increase the percent transduction of the photo-
receptors from approximately 40% to 85% [33].
It is unclear what percent of the total photoreceptor cell
population must be transduced to overcome the phenomen-
on of nonautonomous, density-dependent photoreceptor
degeneration. The results obtained in this study and in other
studies of inherited retinal disease suggest that there may be a
‘‘critical mass’’ of photoreceptor cells that must be preserved
to obtain long-term cell survival. Two factors that seem to
inﬂuence whether a photoreceptor cell lives or dies are the
percent of the total photoreceptor population slated for
death and the topographical position of that cell relative to
the degenerating cells. For example, in the GC1 knockout
mouse, degeneration of the cones, which represent 3%–5%
of the photoreceptor population and are distributed evenly
across the retina, does not adversely affect survival of the rod
cells [53,54]. In humans with rod-speciﬁc retinal degeneration
caused by rhodopsin gene mutations, cone cell function and
survival becomes compromised when greater than 75% of the
affected rod cells degenerate [55]. In human cone dystro-
phies, there can be an impact of degenerating cone cells on
rod cell survival, most evident in the central retina, wherein
both photoreceptors peak in density and are closely adjacent
[56,57]. The notion that therapies producing large contiguous
regions of treated cells aid survival of the treated cells gains
support from the success of subretinal delivery of viral
vectors in studies of mouse [21,24] and dog [20,58] models of
LCA2, a disease caused by mutations in the gene encoding
RPE65. In these studies, the retinal pigment epithelium cells
that normally express RPE65 are the primary targets of
Figure 6. Comparison of Retinal Morphology of Wild-Type RIR, Untreated
GUCY1*B, and Treated GUCY1*B Chickens
(A) The morphology of the retinas of treated animals was examined to
determine if the viral treatment had affected the course of retinal
degeneration. Regions were analyzed along the vertical meridian of the
right eyes of experimental and control animals; representative micro-
graphs from the locus superior to the optic nerve (SUP ON) are shown
from one wild-type, one untreated GUCY1*B, and three treated retinas
(animals 1, 5, and 6). GCL, ganglion cell layer; INL, inner nuclear layer; IPL,
inner plexiform layer; IS, inner segments; ONL, outer nuclear layer; OS,
outer segments; RPE, retinal pigment epithelium.
(B) Relative percent change in retinal thickness of treated animals. Retinal
width (in micrometers) from the outer limiting membrane to the
ganglion cell layer was measured at six loci (100 lm apart) within the
regions examined. These widths were expressed as percent change
relative to average widths of the untreated GUCY1*B retinas in these
regions, which were set to zero for graphing purposes. A simple one-
sample t-test (null hypothesis that treatment groups are not different
from untreated GUCY1*B) was used to analyze the results. The results of
this test showed that retinal thicknesses of the treated animals in the
SUP ON (SON) and INF ON (ION) regions were greater than those of
untreated animals (p , 0.05). Four of six treated animals also showed
evidence of slowing of degeneration in the SUP region, but this was not
statistically significant. The key for animal number is shown in the upper
left of the graph.
DOI: 10.1371/journal.pmed.0030201.g006
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cells. Since each retinal pigment epithelium cell supports the
function of many photoreceptor cells, successful treatment of
the retinal pigment epithelium effectively treats large,
contiguous regions of photoreceptor cells. Other studies
using subretinal delivery to treat primary photoreceptor
diseases have not been able to entirely halt progressive
degeneration [16,18,48]. Although we were able to restore
vision by transducing a relatively low percent of the photo-
receptor population, transduction of a larger percent of these
cells may lead to signiﬁcant improvement in the long-term
effectiveness of our gene therapy.
Another modiﬁcation to our therapeutic strategy that may
improve treatment efﬁcacy is use of photoreceptor-speciﬁc
promoters to drive transgene expression in our viral vector.
Limiting expression of GC1 to photoreceptors could improve
treatment effectiveness by eliminating any untoward effects
induced by ubiquitous GC1 expression. A future strategy
might also include bicistronic therapeutic transgenes that not
only encode GC1 but also encode factors that improve
photoreceptor viability or prevent cell death. Several
members of the ﬁbroblast growth factor family [59,60], ciliary
neurotrophic factor [61], and the apoptotic inhibitor bcl-2
[62,63] have been shown to delay photoreceptor degeneration
in models of inherited retinal disease. Recently, a factor
secreted by rod cells has been identiﬁed that appears to
support cone cell viability [64].
Clinical Relevance to LCA1
The present proof-of-concept experiments in the avian
model of LCA1, albeit with an in ovo approach, prompts
thoughts of translational studies en route to human clinical
trials of gene transfer. The observation that the photo-
receptor transduction efﬁciencies achieved in this study
support near normal visual behavior in the treated animals
is encouraging and consistent with what is well-known
clinically about human retinal degeneration diseases. Despite
major deﬁcits in retinal function, as measured by visual ﬁelds
or ERGs, patients can display serviceable vision if even small
islands of functioning retina are retained [65–67]. Thus, it is
reasonable to expect that restoration of useful vision in LCA1
patients would not require treatment of the entire retina.
Based on human postmortem studies of retinal histopathol-
ogy in an 11.5-y-old patient with LCA1 caused by GUCY2D
mutation [13], in utero gene transfer may not be the only
option in this life-altering but nonfatal ocular disease. This
clinical–pathological analysis showed that there were regions
with preserved retina cells despite profound visual disturb-
ance at this age. Early treatment of pediatric LCA1 patients,
however, would seem worth considering because of a report of
prenatal retinal degeneration in this genotype [68]. Although
serious visual consequences are characteristic of molecularly
deﬁned LCA1 [14,69–71], there are only limited data on the
retinal pathology underlying the major dysfunction in LCA1
[13]. In vivo optical scanning techniques have advanced
sufﬁciently to permit quantiﬁcation of the retinal micro-
pathology present in LCA1 patients with different GUCY2D
mutations. Such studies would be a prerequisite for speciﬁc
planning of future trials of treatment in humans [72].
Finally, the safety and efﬁcacy of virus-based gene transfer
is also a major point of consideration for future studies intent
on developing a genetically based treatment for LCA1 in
humans. To date, several different types of virus-based
vectors have been engineered for effective gene transfer in
vivo. In this study, we chose to use a lentiviral vector system.
Lentivectors efﬁciently and stably transduce retinal progen-
itor cells, a characteristic that made them particularly useful
in our in ovo treatment paradigm. In considering treatments
for human LCA1, it will be important to adopt the vector
system that is best suited for the treatment situation. For
example, vectors based on adeno-associated virus have
proven to be efﬁcient vehicles for gene transfer to retinal
photoreceptors [73–75] and hold promise for clinical trials of
retinal disease in humans [72]. Lentiviral vectors also exhibit
great promise as vehicles for gene therapy [76,77]. A recent
study showing that nonintegrating lentiviral vectors are able
to restore retinal function to a mouse model of LCA2 [78]
signiﬁcantly increases the safety and value of this vector for
human gene therapy applications.
Supporting Information
Video S1. Optokinetic Behaviors of Wild-Type RIR and Untreated
GUCY1*B Chickens
Optokinetic behavior was recorded for wild-type RIR and untreated
GUCY1*B chickens at 21 d of age. High-contrast vertical square wave
gratings with spatial frequencies of 0.065 or 0.26 cycles degree
 1 (bar
widths of 5 cm and 1.25 cm, respectively) were used to elicit responses
from the RIR chicken. Both stimuli induced reﬂexive head movement
characteristic of the optokinetic response in birds. The 5-cm stimulus
was used in tests of the untreated GUCY1*B chicken. No optokinetic
responses were elicited in this animal.
Found at DOI: 10.1371/journal.pmed.0030201.sv001 (4.4 MB MOV).
Video S2. Volitional Visual Behaviors of Wild-Type RIR and
Untreated GUCY1*B Chickens
The visual behaviors of the wild-type RIR chickens were recorded at 7
d of age, and those for the untreated GUCY1*B chicken were
recorded at 7 and 21 d of age. The wild-type RIR chickens oriented to
ﬂags and novel stimuli within their visual ﬁeld but avoided them.
Visually directed pecking was most strongly elicited by food.
Untreated GUCY1*B chickens did not attend to moving stimuli
within their visual ﬁelds. They remained relatively stationary but
when they moved they tended to do so in circles. When the animals
were stationary, slow nystagmiform movements of the head, which
are one of the identifying stereotypic behaviors exhibited by these
animals, were observed.
Found at DOI: 10.1371/journal.pmed.0030201.sv002 (6.8 MB MOV).
Video S3. Optokinetic Behavior of Treated GUCY1*B Animal 2
The optokinetic responses of animal 2 were recorded at 13 d of age.
The vertical square wave grating with a spatial frequency of 0.26
cycles degree
 1 (bar width of 1.25 cm) was used to elicit responses
from animal 2. When placed within the rotating stimulus drum,
animal 2 exhibited reﬂexive head movements characteristic of the
optokinetic response.
Found at DOI: 10.1371/journal.pmed.0030201.sv003 (2.4 MB MOV).
Video S4. Volitional Visual Behaviors of Treated GUCY1*B Animal 2
The visual behavior of animal 2 was recorded at 3, 7, and 13 d of age.
On days 3 and 7, animal 2 pecked at black printed dots on white
paper (1, 2, 4, and 10 mm diameter), visually followed a black dot
centered on a white ﬂag, and pecked at shiny objects. On day 13,
animal 2 repeatedly ran toward a member of the investigative team
a n dp e c k e da ts h i n yo b j e c t s .T h er a p i d ,d i r e c t e dl o c o m o t i o n
exhibited by animal 2 was never observed in untreated GUCY1*B
animals and may have been a manifestation of behavioral imprinting
to the investigator who raised it.
Found at DOI: 10.1371/journal.pmed.0030201.sv004 (8 MB MOV).
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Editors’ Summary
Background. Leber congenital amaurosis (LCA) is the name of a group
of hereditary diseases that cause blindness in infants and children.
Changes in any one of a number of different genes can cause the
blindness, which affects vision starting at birth or soon after. The
condition was first described by a German doctor, Theodore Leber, in the
19th century, hence the first part of the name, and ‘‘amaurosis’’ is
another word for blindness. About 20% of children with LCA have the
most common type, called LCA1, which is caused by defects in a gene
called retinal guanylate cyclase (GUCY2D) that is found on Chromosome
17. It is one of a group of genes that produce proteins that are important
in determining how rods and cones—specialized light receptor cells at
the back of the eye—respond to light, in particular, how they can return
to the resting state after being stimulated by light. Defects in the gene
leave the eye unable to respond to light, and so cause blindness. There is
also damage to the receptor cells, which in turn causes a cellular
breakdown of the retina—the light-sensitive tissue at the back of the
eye. Gene therapy works by replacing a defective gene with a normal
functional one, usually by packaging the normal gene into a harmless
virus and injecting it into the affected tissue, in this case the eye.
Why Was This Study Done? Gene therapy is a promising therapy for
diseases such as LCA, because the gene defect is known and the
damaged cells are still alive but just not functioning properly. In addition,
there is an animal model for LCA1, a strain of chickens with a mutation in
the chicken GUCY2D gene: these chickens develop a disease very similar
to that of humans and can be used to test treatments before they are
tried out in humans.
What Did the Researchers Do and Find? They took a virus and put the
normal GUCY2D gene into it and linked it to a reporter gene (that is a
gene that can be used to check whether the first gene is present). They
then injected this virus into eggs containing chick embryos that had the
abnormal gene, and allowed the chicks to hatch normally. Of seven
chicks injected, six exhibited sight, in contrast to untreated animals,
which were blind. The improvement in the chicks’ sight occurred despite
the fact that only a relatively small amount of normal protein was made
and that normal protein was present in only some of the retinal cells. The
breakdown of the retinas in the treated chicks also appeared to be
slower than in untreated chicks.
What Do These Findings Mean? This study shows that in theory it is
possible to treat a form of childhood blindness caused by a photo-
receptor gene defect by gene therapy. Because this study was done in
chickens, many other steps need to be taken before it will be clear
whether the treatment could work in humans. These steps include a
demonstration that the virus is safe in humans, and experiments that
determine what dose of virus would be needed and how long the effects
of the treatment would last (the chicks were only studied for 6–7 weeks).
Another question is whether it would be necessary (or even possible) to
treat affected children before birth, or whether therapy in infants could
restore their sight. In addition, the treatment would obviously only work
for children who had this specific type of blindness, but many of the
principles learned from studying LCA1 should be applicable to other
types of LCA and possibly other types of inherited blindness.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030201.
  The Foundation for Retinal Research has detailed information on LCA
  The Foundation Fighting Blindness funds research into, and provides
information on, many types of blindness, including LCA
  Contact a Family, a United Kingdom organization that aims to put
families of children with illnesses in touch with each other, has a page
of information on LCA
  RetNet—Retinal Information Network—is a comprehensive resource
describing current knowledge of all inherited retinal diseases
  Fight for Sight funds student and post-doctoral fellowships as well as
grant-in-aid to persons whose research focuses on curing and
preventing blindness
  WebVision is a Web site that provides a comprehensive resource for
understanding the organization and function of the retina and visual
system
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